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Lagrange and his coworkers [ l ]  have compared the 
serologic reactions to three mycobacterial glycolipid 
antigens prepared by the Pasteur Institute with the 
reaction to a commercially available protein antigen 
(A60). This study presents several interesting obser- 
vations but the conduct of the investigation and the 
sweeping conclusion drawn deserve comment. 
First, the mode of use of the A60 test clearly 
exposes the interspecific character of the protein 
antigen, the detection of inapparent inycobacterial 
infections in healthy exposed groups and the need to 
evaluate the serologic results in conjunction with other 
laboratory and clinical observations. Emphasis is placed 
on the sero-analysis of immunodepressed and ini- 
munosuppressed subjects, who produce small amounts 
of IgA antibodies against A60; the search for IgA anti- 
bodies is warranted and would increase the diagnostic 
power in extrapulnionary cases, in HIV-seropositive 
cases and in the AIDS syndrome. The reproach cannot 
be made that the limitations of the commercial ELISA 
test have been concealed by the manufacturer. It is not 
possible that Lagrange et a1 were ignorant of these 
established limitations, and one would have expected 
that a study that confirmed them would have included 
these previous observations in the introduction. 
Second, the corrective measures to be applied in 
the serologic A60 analysis of irnmunodepressed cases 
are clearly set out in the instructions for use of the 
antigen. A comparison purporting to demonstrate the 
absolute superiority of the three non-peptide antigens, 
which are not generally available, over this commercial 
protein antigen should have followed these recomnien- 
dations, when indicated. However, no search for IgA 
antibodies was made in HIV-positive cases, as recom- 
mended, while the cut-offs for IgM and IgG antibodies 
were not decreased but considerably increased, to 100% 
specificity. 
Third, I note that the ordinates of the figures have 
no scale and thus suggest that the serologic responses 
were identical in intensity for all the antigens used- 
when in fact they varied widely within the same patient 
groups. For example, the mean absorbance for HIV- 
negative, sputum smear-positive extrapulmonary cases 
was 0.041 with the PGLTb antigen and 0.527 with 
A6O. The presentation of these data as 41 and 527 and 
their statistical manipulation is misleading: an ELISA 
absorbance value of 0.041 is, for all practical purposes, 
a blank. The P value included under this entry in Table 
1 should in fact be 0.05 rather than 0.001. All these 
values were obtained at a wavelength of 414 nin, which 
is inappropriate for the A60 test, the optimum for 
which is 450 nm. At 414 nni the intensity of the 
absorbance is reduced two- to three-fold, and uncertain 
results are obtained in the low-density range, precisely 
where the cut-off is estimated. 
Another discrepancy is the claim that all the 
patients infected by Mycobacfrrium spp. other than 
tuberculosis (MOTT) included in this study were HIV 
positive with disseminated disease (page 215) set against 
the observation that the specificity of A60 was about 
80% (in truth 83.3%) in HIV-negative patients with 
localized MOTT infection (page 219). 
Fourth, the statistical analysis relies on the pre- 
mise that all TB-culture-positive cases are ‘tuberculosis 
(TB) cases’ while all TB-culture-negative cases are 
‘controls’. The data given in the tables show a few 
differences among patient groups for some antigens, 
but most groups gave similar mean absorbances, at 
least if their SEM is taken into account. Lagrange et a1 
understand that TB patients may differ in their response 
and subdivide them according to bacteriologic and 
clinical criteria but they do not apply this concept to 
the various extrapulmonary locations analyzed by A60 
and LOS antigens. The SEM of the A60 absorbance is 
very large (0.344 for a mean of 0.527) and is even larger 
for the LOS antigen: 0.0749, almost equal to the mean, 
which could bring the mean 0.0910 down to 0.016, 
where it would rejoin blank values. These two large 
SEM values indicate that, for these two antigens, all 
the extrapulmonary cases cannot be drawn into a 
single group. Similarly, Lagrange et a1 do not apply 
the concept either to control groups; they pool all 
‘negative’ cases and define a cut-off for serologic 
data at 100% specificity. This runs counter to the 
spirit of a statistical analysis which deliberately takes 
into account the unavoidable variations occurring in 
biological material and among individual samples. In 
doing so, they considerably diminish the sensitivity and 
usefulness of a recognized interspecific antigen. They 
disregard the possibility of abacillary TB, ignore the 
possibility of positive serology due to MOTT, do not 
take into account the possibility of abortive infections 
in control groups at risk of infection but prone to 
be blood donors (airline stewards, policemen, social 
workers, supermarket employees, clinicians, nurses), 
neglect the impact of immunodepression on HIV- 
positive controls and claim species specificity for the 
three in-house lipid antigens, although DAT antigen 
reacts with leprosy sera (reference 19) and anti-PGL 
antiserum reacts with lipidic extracts of M.  bovis, BCG, 
M.  xenopi, M.-fiavescenr and M.-fallax. 
Fifth, the dynamic aspects of antibody production 
are not considered. The poor sensitivity of the protein 
antigen reported by Lagrange et al. in contrast to the 
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results reported in the literature, is not due solely to 
statistical misuse but is real and is interesting yet is not 
discussed by Lagrange et al. It is most probably due 
to the timing of the serologic tests. A60 antigen is 
dominant during human disease and serologic testing 
with A60 is applied to patients who consult because 
they have symptoms; the serologic results obtained 
must be evaluated together with clinical clues, as 
recommended. The criteria for selection of patients 
and controls applied by Lagrange et a1 are not stated. 
Presumably the search was diverted towards asymp- 
tomatic TB cases in conjunction with suspicion of 
HIV infection. One may safely predict that the fre- 
quency of anti-A60 seropositives would increase with 
the appearance of symptoms and also in HIV-positive 
cases with chronic TB, while the frequency of positive 
cases detected with the non-peptide antigens would be 
higher in healthy people with no other sign of infection, 
with an extension of the search to TB-risk groups. 
Sixth, a most disturbing aspect of this comparative 
analysis is the absence of publication of the D T H  data 
that were collected on TB patients. Lagrange et al. 
omitted this search in control groups, thereby ignoring 
the possibility of BCG vaccinations and inapparent or 
past infections. Equally worrying is the absence of 
statistical analysis on the usefulness of combing protein 
antigens with non-peptide antigen in ELISA. Such 
information could have been provided and would have 
contributed substantially to our understanding of the 
immunologic processes and also, if an additive effect 
were observed, improved the system of detection. 
Kesearch into human tuberculosis is difficult and 
frustrating. The investigation of Lagrange et a1 repre- 
sents a welcome departure from traditional research 
concerns, even if it presents substantial deficiencies. It 
contributes to a better understanding of the immuno- 
pathology of the disease. In the face of discrepant 
findings, what must be avoided now is a grand sweep 
of induction that extracts general laws from limited 
observations with preparations the properties of which 
have not yet been completely defined. 
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The object of this study was to compare the relative 
efficiency of different peptide and non-peptide antigens 
in an ELISA test in hospitalized patients presenting 
with mycobacterial disease and with a bacteriologically 
proven diagnosis. The controls were healthy blood 
donors without dagnosed tuberculosis and not treated 
during the preceding 5 years. The controls with 
pulmonary afAictions were patients whose samples 
(expectoration, bronchoscopy, bronchoalveolar lavage), 
including the repeats, turned out to be negative. None 
of them had received antituberculosis antibiotic therapy. 
The notion of HIV seropositivity was included in this 
study only retrospectively, on the basis of patient 
records, in order to verify whether these ELISA tests 
were applicable to all cases in which active tuberculosis 
had been diagnosed, and independently of the know- 
ledge of the immune status with respect to HIV. 
Demonstration of anti-A60 IgA was not attempted in 
this study since the only document published at the 
time of our study was that by Gupta et a1 [l] which 
showed equivalence between IgG and IgA. This has 
been subsequently confirmed in an Italian study 121. 
Furthermore, the recommendation to test for anti-A60 
IgA in HIV-positive subjects does not seem to be 
documented, and in any case, does not appear in the 
two above-mentioned publications. 
As far as the absence of graduation of the ordinate 
in Figures 1 and 2 is concerned, this is a typographical 
error. At any rate, this is of little importance and the 
cut-off levels are indicated. These have not been chosen 
randomly, but have been calculated according to 
established procedures using the mean of the results 
of the ODs of the blood donors plus two standard 
deviations. These cut-off levels, and in particular those 
for anti-A60 IgGs, are identical to those found by other 
authors [2]. They have been given in Tables 2 to 5. 
The conditions for reading the ELISA A60 plates were 
those recommended by the manufacturer and readings 
were done at 450 nm, and not at 414 nm, the wave- 
length used exclusively for the reading of ELISAs using 
the glycolipid antigens. The use of these cut-off levels 
has allowed the comparison of the sensitivities of 
the different tests, using one comparable specificity. 
Furthermore, the comparison of the means of the 
antibody titers, in various clinical-biological situations 
(pulmonary and extrapulmonary tuberculosis, sero- 
positivity and -negativity with respect to HIV, positive 
or negative direct examination) has been carried out 
in order to attempt the evaluation of the influence of 
these situations on the antibody response measured by 
the OD with respect to each antigen tested. As has 
